Background: This study examines the effect of interstitial inflammation and interstitial fibrosis and tubular atrophy on renal survival in lupus nephritis.
Introduction
Lupus nephritis is a significant contributor to morbidity and mortality in patients with systemic lupus erythematosus (SLE) and disproportionately affects African Americans [1, 2] . Approximately 38% of patients with SLE develop lupus nephritis and at least 10% of these patients progress to end-stage renal disease (ESRD) within 10 years [3] . Lupus nephritis is separated into classes based on histologic criteria established by the International Society of Nephrology and the Renal Pathology Society (ISN/RPS) [4] . The ISN/ RPS classification focuses predominantly on glomerular lesions in defining disease activity and chronicity. Interstitial inflammation and interstitial fibrosis are graded as mild, moderate and severe, but there are no criteria for these categories and it is unclear how they affect prognosis independent of ISN/RPS class.
First-line treatment for patients with Class III or IV lupus nephritis is induction therapy with intravenous cyclophosphamide or mycophenolate mofetil in combination with steroids, followed by maintenance therapy with mycophenolate mofetil or azathioprine supported by oral steroids [5] . Alternative immunosuppressive agents, including rituximab, cyclosporine and tacrolimus may be used for refractory lupus nephritis or in patients who cannot tolerate first-line therapy [6] [7] [8] [9] . Adjunctive therapies include renin-angiotensin system blockade, blood pressure control and statins for hyperlipidemia. The presence or absence of interstitial inflammation, interstitial fibrosis and tubular atrophy and chronic glomerular lesions is not routinely used to make therapeutic decisions and may provide insight into the risk for disease progression.
Materials and methods

Study population
This retrospective study included 301 patients with biopsyproven lupus nephritis consecutively diagnosed at Yale New Haven Hospital, New Haven, CT, USA from 1 January 1998 to 31 December 2014. Patients biopsied prior to 1 January 1998 were excluded. All patients met at least four of the American College of Rheumatology 1997 criteria for SLE.
Histologic classification
Initial (n ¼ 301) and repeat biopsies (n ¼ 94) were categorized by ISN/RPS 2003 criteria by two independent pathologists [4] . Disagreements were adjudicated by consensus. All biopsies had at least 10 glomeruli for evaluation. Interstitial inflammation and interstitial fibrosis and tubular atrophy were graded semiquantitatively by hematoxylin (H&E) and eosin, periodic acid-Schiff (PAS), silver and trichrome stains using the following categories: Grade 0: 5%; Grade 1: 5-25%; Grade 2: 25-50%; Grade 3: >50% (see Supplementary data for representative images). The categories represent the percentage of nonscarred cortical area involved by mononuclear cell infiltrate and are analogous to the Banff interstitial inflammation scores for kidney allograft rejection [10] . The trichrome stain was used to help identify fibrosis. Areas that cannot be meaningfully graded for interstitial inflammation, including subcapsular cortex and the adventitia surrounding large vessels or lymphatics, were not included in the assessment. All biopsies were assessed by light, immunofluorescent and electron microscopy.
Renal survival
Estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) equation.
ESRD was defined as an eGFR <15 mL/min/1.73 m 2 for at least 3 months. Renal replacement therapy (RRT) was defined as dialysis for >6 months or kidney transplant. CKD was defined as an eGFR <60 mL/min/1.73 m 2 according to the Kidney Disease:
Improving Global Outcomes guidelines [11] . Death was defined as all-cause mortality. Renal survival was defined as the time from initial kidney biopsy to any of the following: ESRD, dialysis for >6 months or kidney transplant.
Statistical analyses
For the composite outcome (ESRD, RRT), time-to-event analysis was performed. Patients with Class VI on initial biopsy (n ¼ 2) were excluded. Variables were assessed by univariate proportional hazards regression and P < 0.05 was considered significant. Complete cases analysis was used to generate the first multivariable model. Multiple imputation was used to estimate missing baseline serum creatinine values before making the second model (see Supplementary data, Methods).
Results
Renal survival, race and ethnicity 
Renal survival and ISN/RPS class
Patients with Class IV had increased serum creatinine and proteinuria and decreased hematocrit, serum albumin and C3 complement relative to patients without Class IV (Table 1) . Class IV on initial biopsy had worse renal survival compared with nonClass IV [HR 2.19 (95% CI 1.22-3.95)], especially in patients with both active and chronic glomerular lesions [ Figure 1B ; Class IV- (26) 10 (14) 27 (43) 2 (10) 6 ( 
Renal survival and tubulointerstitial lesions
Interstitial inflammation was associated with worse renal survival in all patients [ Figure 2A ; relative to interstitial inflammation <5%: interstitial inflammation 5-25%, HR 2.36 (95% CI 1. . Severe interstitial inflammation was more common in Class IV compared with Class III and was uncommon in Classes II and V (Table 1 ). There was a significant correlation between interstitial inflammation grade and IFTA category (r ¼ 0.499, P < 0.001) and a weaker correlation with serum creatinine (r ¼ 0.306, P < 0.001), 24-h protein (r ¼ 0.292, P ¼ 0.002) and hematocrit (r ¼ À0.274, P ¼ 0.002). There was a clear trend between increased interstitial inflammation grade and elevated serum creatinine in patients with Class IV (Supplementary data, Table S3 ; Class IV with interstitial inflammation <5%, 1.41 mg/dL; interstitial inflammation 5-25%, 1.44 mg/dL; interstitial inflammation 25-50%, 2.00 mg/dL; interstitial inflammation >50%, 2.37 mg/dL; F ¼ 2.8, P ¼ 0.047).
Interstitial fibrosis and tubular atrophy was associated with worse renal survival in all patients ( Figure 2C ; IFTA 5-25% HR 3.93 (95% CI 1.58-9.75); IFTA 25-50%: HR 4.01 (95% CI 1.37-11.70); IFTA >50%, HR 13.99 (95% CI 4.91-39.83)] and those with Class IV ( Figure 2D ; IFTA 5-25%, HR 3.93 (95% CI 1.58-9.75); IFTA 25-50%, HR 4.01 (95% CI 1.37-11.70), IFTA >50%, HR 13.99 (95% CI 4.91-39.831)] in a dose-dependent manner. Severe IFTA was more common in Class IV compared with Class III or Class V and was uncommon in Class II (Table 1) . Among patients with Class IV, IFTA category was significantly correlated with increased serum creatinine (F ¼ 2.91, P ¼ 0.041), increased proteinuria (F ¼ 3.7, P ¼ 0.017) and increased age (F ¼ 3.7, P ¼ 0.013) at the time of biopsy. 77 (10) 79 (10) 78 (11) 80 (14) 79 (13) 78 (12) 78 (12) C3 (mg/dL) 98 (36) 121 (29) 99 (36) 91 (31) 76 (37) 94 (34) 103 (30) C4 (mg/dL) 20 (10) 24 (11) 25 (13) 19 (11) 13 (11) 18 (6) (6) 2 (10) 2 (11) 10 (14) 24 (38) 3 (16) 9 (15) All-cause death, total n (%)
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Class IV, IFTA category, interstitial inflammation grade, proportion of globally sclerosed glomeruli, serum creatinine, elevated blood pressure, serum albumin, hematocrit and 24-h protein were each associated with renal survival in univariate analysis (Table 3 ). Blood pressure, serum albumin, hematocrit and 24-h protein were excluded from the multivariable model due to missing data (Supplementary data, 
Tubulointerstitial lesions and risk categorization
To visualize how interstitial inflammation and IFTA affect renal survival, patients were separated into three risk categories based on biopsy findings (Table 4) and outcomes  (Supplementary data, Tables S6 and S7 ). Patients with the lowest risk for renal failure and mortality had the least severe tubulointerstitial lesions (green category in Table 4 ), whereas patients with the highest risk for renal failure and mortality had the most severe tubulointerstitial lesions (red category in Table  4 ). An increased proportion of patients with Class III and IV Table 4 . Risk categories for renal survival by interstitial inflammation and interstitial fibrosis and tubular atrophy on initial biopsy (n ¼ 301)
Number of patients (% total) 
The value of repeat biopsy
A total of 94 patients underwent repeat biopsy and the median time between biopsies was 2.6 years. All repeat biopsies were indication biopsies for persistent or worsening renal insufficiency and proteinuria. A 'clinically significant' class switch from a non-Class III/IV lesion to Class III/IV or III/IV þ V occurred in 6 of 11 patients with Class II and 6 of 17 patients with Class V on the first biopsy (Table 5 ). In contrast, 17 of 66 patients with Class III/IV on the first biopsy switched to Class II or V. A minority of these patients (6/17) had globally sclerosed glomeruli on repeat biopsy but no evidence of fibrous Table 5 . ISN/RPS class on index and repeat biopsy (n ¼ 94) Figure 4B ; HR 1.96 (95% CI 1.40-2.75)] and in those with Class IV on initial biopsy [HR 3.24 (95% CI 1.73-6.07)]. To determine if the interstitial risk category was predictive of renal survival at repeat biopsy, patients were grouped into categories as previously described ( Table 7 ). The interstitial risk category was a significant predictor of renal survival at repeat biopsy in all patients [ Figure 4C ; relative to low risk: intermediate risk, There was a correlation between interstitial inflammation on the first biopsy and IFTA on the second biopsy (r ¼ 0.433, P < 0.001). Interstitial inflammation grade on the first biopsy was significantly associated with IFTA category on the second biopsy independent of age, gender, race, ethnicity and IFTA category on the first biopsy [interstitial inflammation on the first biopsy: odds ratio (OR) 1.61 (95% CI 1.04-2.47); IFTA on the first biopsy: OR 2. 23 (95% CI 1.24-3.99) ]. In other words, for a unit increase in interstitial inflammation grade on the initial biopsy, a patient is approximately 1.6 times as likely to have an increase in IFTA category on repeat biopsy.
Discussion
The utility of kidney biopsy has been questioned since increasingly sensitive and specific laboratory testing is available for the diagnosis of lupus nephritis. This study demonstrates the independent prognostic value of interstitial inflammation and IFTA after adjusting for established risk factors for renal survival, including race, ethnicity, age and elevated serum creatinine. Increased interstitial inflammation grade or IFTA category stratified risk for renal survival in all patients and those with ISN/RPS Class IV on initial and repeat biopsy. For a unit increase in inflammation grade or IFTA category, there was an $1.5-to 2-fold increased rate of renal death during the study period.
The ISN/RPS classification has been criticized for focusing predominantly on glomerular lesions when tubulointerstitial lesions better predict renal survival [12] [13] [14] [15] [16] [17] [18] [19] . Many studies have relied on the National Institutes of Health (NIH) chronicity index to demonstrate the effect of renal scarring on outcomes, however, the NIH chronicity index is a composite score of glomerular and tubulointerstitial injury that does not convey the dominant effect of IFTA [15] . In our study, ISN/RPS Class IV was a significant predictor of renal survival in univariate analysis and patients with both active and chronic glomerular lesions (IV-AC) had worse renal survival than patients with only active lesions (IV-A). These data complement the report by Hiramatsu et al. [20] , which showed that chronic glomerular lesions are a key determinant of response to therapy in Class IV [20] . However, Hiramatsu et al. did not systematically evaluate tubulointerstitial lesions. In fact, neither Class IV nor the proportion of glomeruli with chronic lesions was a significant predictor of renal survival after adjusting for interstitial inflammation grade and IFTA category in our multivariable models. One potential explanation is that a significant portion of the risk attributable Table 7 . Risk categories for renal survival on repeat biopsy (n ¼ 94)
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38 (40) 13 (13) to ISN/RPS Class IV is due to the increased frequency of severe tubulointerstitial lesions (Table 1 ). Similar to our study, Yu et al. [21] showed that patients with Class IV have an increased proportion of moderate to severe tubulointerstitial lesions and that glomerular sclerosis was not a significant predictor of renal outcome after adjusting for interstitial inflammation, interstitial fibrosis or tubular atrophy [21] . In our experience, there were very few patients (4%) with significant glomerulosclerosis (>30%) that did not have any IFTA (<5%), which suggests that IFTA may be a more sensitive indicator of kidney injury. Tubulointerstitial lesions progress on repeat biopsy. In our study, 54% of patients had increased IFTA on their second biopsy. Furthermore, interstitial inflammation on the first biopsy was independently associated with increased IFTA on the second biopsy and approximately two-thirds of the patients with moderate to severe interstitial inflammation on the second biopsy (interstitial inflammation 25-50% or interstitial inflammation >50%) had mild or absent inflammation on the first biopsy (interstitial inflammation 5-25% or interstitial inflammation <5%). In a large repeat biopsy study (n ¼ 142), Pagni et al. [22] showed that patients with Class IV are more likely to have interstitial inflammation on the first biopsy and increased interstitial fibrosis on the second biopsy. These data suggest that increased inflammation leads to fibrosis but are limited by the fact that many patients were biopsied for worsening renal insufficiency or proteinuria. Some authors advocate for protocol biopsies after induction or maintenance therapy to assess response to treatment, whereas others prefer to reserve repeat biopsy for renal flares [23] [24] [25] [26] [27] [28] [29] [30] . In general, these studies have shown that clinical variables do not predict histologic remission, a change in ISN/RPS class during renal flare is not uncommon and most patients show progression of the chronicity index. However, few studies have critically examined interstitial inflammation as a predictor of long-term renal outcome. Notably, Alsuwaida et al. [31] showed that increased interstitial inflammation on repeat biopsy at 12-18 months was a poor predictor of renal survival. These findings are similar to our study, which showed that both interstitial inflammation and IFTA are significant predictors of renal survival in all patients undergoing repeat biopsy and in those with Class IV on the first biopsy.
Tubulointerstitial lesions are important predictors of renal survival in diseases other than lupus nephritis. The Oxford Classification of immunoglobulin A (IgA) nephropathy uses semiquantitative grading of interstitial fibrosis and tubular (T)-score, which has been shown to strongly predict renal survival in meta-analysis [32, 33] . Increased interstitial inflammation has also been shown to predict disease progression in IgA nephropathy [34] . Inflammatory cells in the interstitium assemble into aggregates that may worsen tissue injury by enhancing antigen presentation and autoantibody production [35] . Interstitial inflammation has been implicated in membranous nephropathy, acute and chronic interstitial nephritis, allograft rejection and lupus nephritis [36] [37] [38] . Interestingly, interstitial inflammation in lupus nephritis does not appear to be related to tubulointerstitial immune deposits but may be caused by autoantibodies to interstitial antigens like vimentin [39, 40] . Interstitial inflammation can occur in the absence of glomerular inflammation and these studies suggest that preventing the development of tubulointerstitial lesions may be a therapeutic target in lupus nephritis (recently reviewed by Clark et al. [13] ).
The reproducibility of interstitial lesion grading is a significant limitation [32, 41] . On the one hand, intragrade correlation coefficients (ICCs) for interstitial inflammation (ICC ¼ 0.58) and IFTA (ICC ¼ 0.78) were considered 'good' or 'very good' by the Oxford IgA Nephropathy Working Group and are similar to values from our study (interstitial inflammation ICC ¼ 0.67, IFTA ICC ¼ 0.65). The values from our study represent an interobserver agreement of approximately 77% [41] . On the other hand, this level of reproducibility has been criticized as too unreliable for clinical use. The majority of disagreements in our study were the result of a grading change from absent to mild or mild to moderate and infrequently resulted in a change in risk category ($19%). Reproducibility of ISN/RPS class further complicates risk stratification and the clinical utility of grading interstitial lesions has not been established [42, 43] .
Recent studies by Hsieh et al., [12] Yu et al. [21] and Alsuwaida et al. [24] have shown that semiquantitative grading of IFTA and interstitial inflammation are the key predictors of renal survival over and above the NIH activity and chronicity index. Hsieh et al. [12] compared CD45 staining to modified light microscopy, which uses standard immunohistochemistry to quantify interstitial inflammation in areas away from fibrosis, and found that CD45 staining helps distinguish between the intermediate categories of interstitial inflammation. Renal survival analysis was similar between methods, but the increased sensitivity of CD45 staining nearly eliminated patients from the lower tiers of interstitial inflammation (0% and <10%) compared with modified light microscopy where patients were more evenly spread across groups. Nevertheless, our study showed similar results using modified light microscopy and expanded on these findings by examining how tubulointerstitial lesions affect renal survival in a subset of patients with ISN/RPS Class IV. This is an important distinction because patients with Class IV have a larger proportion of moderate to severe tubulointerstitial lesions and are more likely to receive immunosuppressive therapy, which could potentially confound the survival analysis. Hsieh et al. [12] , Yu et al. [21] and Alsuwaida et al. [24] grouped all ISN/RPS classes together when they reported the effect of tubulointerstitial lesions on renal survival. Hsieh et al. (n ¼ 68) and Alsuwaida et al. (n ¼ 73) were limited by sample size, whereas Yu et al. (n ¼ 313) published the largest study looking at IFTA and interstitial inflammation in lupus nephritis [21] . When comparing our study with Yu et al. [21] , there was a similarsized patient population, age at initial biopsy and mean follow-up time. Our study had fewer patients with Class III/IV [172/301 (57%) versus 225/313 (72%); P < 0.001], an increased proportion of patients with chronic glomerular lesions [III/IV-AC: 82/172 (47%) versus 76/225 (34%); P ¼ 0.005] and a similar proportion of severe tubulointerstitial lesions [interstitial inflammation >50%: 31/301 (10%) versus 24/313 (8%); IFTA >50%: 18/301 (6%) versus 17/313 (5%)], which led to modestly worse renal survival [ESRD or RRT: 54/301 (18%) versus 37/313 (12%); P ¼ 0.04] and more patients that died in long-term follow-up [40/301 (13%) versus 3/301 (1%); P < 0.001]. Our study consisted of a mix of African American, Hispanic and nonHispanic Whites, whereas their study was predominantly Asian. Yu et al. [21] placed patients into groups based on the severity of active glomerular lesions and active or chronic tubulointerstitial lesions, which makes it difficult to compare the independent effects of interstitial inflammation and IFTA on renal survival. Furthermore, they did not incorporate both of these variables into any of their multivariable models. However, despite significant differences, all of these studies showed a dose-dependent decrease in renal survival as interstitial inflammation or IFTA increased and may help to define the contribution of tubulointerstitial lesions within the ISN/ RPS classification of lupus nephritis.
